Li Jing-Bo, Xia Wen-Fei
The Second Clinical Medical School of Shandong University, Jinan, 250033, China.
Department of Breast and Thyroid Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Curr Med Sci. 2025 Aug 25. doi: 10.1007/s11596-025-00094-4.
The heterogeneity of triple-negative breast cancer (TNBC) has spurred the exploration of precision therapies based on molecular subtypes, with the androgen receptor (AR)-positive subtype emerging as a potential therapeutic target. The treatment of AR-positive TNBC relies primarily on androgen receptor antagonists, such as enobosarm, bicalutamide, and enzalutamide. To enhance efficacy, researchers are investigating combination therapies that integrate anti-androgen agents with chemotherapy, immunotherapy, or PARP inhibitors. Additionally, studies have revealed that the AR signaling pathway regulates the tumor microenvironment, and AR inhibition may potentiate the efficacy of immune checkpoint inhibitors. However, anti-AR therapies face significant limitations and challenges due to multifaceted factors, necessitating further resolution. With continued advancements, AR-targeted therapy holds promise as a critical component of personalized treatment strategies for TNBC.
三阴性乳腺癌（TNBC）的异质性推动了基于分子亚型的精准治疗探索，雄激素受体（AR）阳性亚型成为一个潜在的治疗靶点。AR阳性TNBC的治疗主要依赖于雄激素受体拮抗剂，如恩杂鲁胺、比卡鲁胺和恩扎卢胺。为提高疗效，研究人员正在研究将抗雄激素药物与化疗、免疫治疗或PARP抑制剂相结合的联合疗法。此外，研究表明AR信号通路调节肿瘤微环境，抑制AR可能增强免疫检查点抑制剂的疗效。然而，由于多方面因素，抗AR治疗面临重大局限和挑战，需要进一步解决。随着不断进步，AR靶向治疗有望成为TNBC个性化治疗策略的关键组成部分。
